RenovoRx (RNXT) Stock Price, News & Analysis

Company Overview

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

Key Stats

• Today's Range: $1.29 to $1.37
• 50-Day Range: $0.96 to $1.42
• 52-Week Range: $0.75 to $1.69
• Volume: 93,331 shs
• Average Volume: 99,476 shs
• Market Capitalization: $49.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.25
• Consensus Rating: Buy

RenovoRx Stock Analysis - MarketRank™

RenovoRx scored higher than 58% of companies evaluated by MarketBeat, and ranked 433rd out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

RenovoRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

RenovoRx has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for RenovoRx are expected to decrease in the coming year, from ($0.40) to ($0.46) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of RenovoRx is -3.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of RenovoRx is -3.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

RenovoRx has a P/B Ratio of 7.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.39% of the float of RenovoRx has been sold short.

Short Interest Ratio / Days to Cover

RenovoRx has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in RenovoRx has recently decreased by 17.98%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

RenovoRx does not currently pay a dividend.

Dividend Growth

RenovoRx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.39% of the float of RenovoRx has been sold short.

Short Interest Ratio / Days to Cover

RenovoRx has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in RenovoRx has recently decreased by 17.98%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, RenovoRx insiders have bought more of their company's stock than they have sold. Specifically, they have bought $119,618.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 9.13% of the stock of RenovoRx is held by insiders.

Percentage Held by Institutions

Only 3.10% of the stock of RenovoRx is held by institutions.

RNXT Stock Analysis - Frequently Asked Questions

How have RNXT shares performed this year?

RenovoRx's stock was trading at $1.29 at the beginning of the year. Since then, RNXT stock has increased by 4.7% and is now trading at $1.35.

How were RenovoRx's earnings last quarter?

RenovoRx, Inc. (NASDAQ:RNXT) announced its quarterly earnings results on Thursday, May, 15th. The company reported ($0.08) EPS for the quarter, hitting analysts' consensus estimates of ($0.08). The firm had revenue of $0.20 million for the quarter, compared to analysts' expectations of $0.23 million.
Read the conference call transcript.

When did RenovoRx IPO?

RenovoRx (RNXT) raised $18 million in an IPO on Thursday, August 26th 2021. The company issued 1,800,000 shares at a price of $9.00-$11.00 per share. Roth Capital Partners and Maxim Group LLC served as the underwriters for the IPO.

How do I buy shares of RenovoRx?

Shares of RNXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of RenovoRx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that RenovoRx investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), Bakkt (BKKT), NIO (NIO) and Phunware (PHUN).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/05/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RNXT
• CIK: 1574094
• Web: www.renovorx.com
• Phone: 650-284-4433
• Fax: 650-397-4433
• Employees: 6
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $7.25
• High Stock Price Target: $11.50
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +437.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.81 million
• Net Margins: N/A
• Pretax Margin: -4,232.50%
• Return on Equity: -119.58%
• Return on Assets: -88.01%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.07
• Quick Ratio: 9.07

Sales & Book Value

• Annual Sales: $40 thousand
• Price / Sales: 1,234.24
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.19 per share
• Price / Book: 7.11

Miscellaneous

• Outstanding Shares: 36,570,000
• Free Float: 33,233,000
• Market Cap: $49.37 million
• Optionable: Not Optionable
• Beta: 1.27